Blister pack with dollars instead of pills In the midst of a pandemic, the drug industry is likely at least in the short term to see a boost to its bottom lines. (Photo: Shutterstock)

Just as other products have seen sales and profits go through the roof as people stocked up on goods in response to lockdowns, pharmaceutical company Eli Lilly has not only beat quarterly estimates but also boosted its profit forecast for 2020 as customers have stocked up on such drugs as its diabetes drug Trulicity and psoriasis drug Taltz.

According to a Reuters report, the company did warn that the phenomenon would likely reverse over the course of the year and it could still be hit with a negative impact to drug prices given the toll coronavirus is taking on the economy.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

More from this author


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2022 ALM Global, LLC. All Rights Reserved.